Fig. 3From: Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trialOverall survival of the DP group and the PF groupDP: docetaxel plus cisplatin; OS: overall survival; PF: cisplatin plus 5-FUBack to article page